Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2023 Aug 26

PMID 37630401

Authors

Emilia Kwiecien

Dorota Kowalczuk

Affiliations

Soon will be listed here.

Abstract

Dermatological diseases pose a significant burden on the quality of life of individuals and can be challenging to treat effectively. In this aspect, cannabinoids are gaining increasing importance due to their therapeutic potential in various disease entities including skin diseases. In this synthetic review, we comprehensively analyzed the existing literature in the field of potential dermatological applications of a lesser-known subgroup of cannabinoids, the so-called minor cannabinoids, such as cannabidivarin (CBDV), cannabidiforol (CBDP), cannabichromene (CBC), tetrahydrocannabivarin (THCV), cannabigerolic acid (CBGA), cannabigerol (CBG), cannabielsoin (CBE), cannabimovone (CBM) or cannabinol (CBN), while drawing attention to their unique pharmacological properties. We systematically searched the available databases for relevant studies and analyzed the data to provide an overview of current thematic knowledge. We looked through the full-text, bibliographic and factographic databases, especially Scopus, Web of Science, PubMed, Polish Scientific Journals Database, and selected the most relevant papers. Our review highlights that minor cannabinoids exhibit diverse pharmacological activities, including anti-inflammatory, analgesic, antimicrobial, and anti-itch properties. Several studies have reported their efficacy in mitigating symptoms associated with dermatological diseases such as psoriasis, eczema, acne, and pruritus. Furthermore, minor cannabinoids have shown potential in regulating sebum production, a crucial factor in acne pathogenesis. The findings of this review suggest that minor cannabinoids hold therapeutic promise in the management of dermatological diseases. Further preclinical and clinical investigations are warranted to elucidate their mechanisms of action, determine optimal dosage regimens, and assess long-term safety profiles. Incorporating minor cannabinoids into dermatological therapies could potentially offer novel treatment options of patients and improve their overall well-being.

Citing Articles

Topical Medications for Chronic Itch in Older Patients: Navigating a Pressing Need.

Bartley B, Pierce C, Hivnor C, Valdes-Rodriguez R Drugs Aging. 2025; 42(3):213-233.

PMID: 39883297 DOI: 10.1007/s40266-024-01174-1.

Anti-Inflammatory Effects of Cannabigerol In Vitro and In Vivo Are Mediated Through the JAK/STAT/NFκB Signaling Pathway.

Jeong G, Kim K, Lee J Cells. 2025; 14(2).

PMID: 39851511 PMC: 11764157. DOI: 10.3390/cells14020083.

Medical cannabis: From research breakthroughs to shifting public perceptions and ensuring safe use.

Hossain M, Chae H Integr Med Res. 2024; 13(4):101094.

PMID: 39640076 PMC: 11617882. DOI: 10.1016/j.imr.2024.101094.

Cannabis-Based Phytocannabinoids: Overview, Mechanism of Action, Therapeutic Application, Production, and Affecting Environmental Factors.

Jurga M, Jurga A, Jurga K, Kazmierczak B, Kusmierczyk K, Chabowski M Int J Mol Sci. 2024; 25(20).

PMID: 39457041 PMC: 11508795. DOI: 10.3390/ijms252011258.

Cannabis-Containing Cream for CKD-Associated Pruritus: A Double-Blind, Placebo Controlled Trial.

Anumas S, Kuropakornpong P, Chakkavittumrong P, Tasanarong A, Pattharanitima P Kidney Med. 2024; 6(10):100894.

PMID: 39328960 PMC: 11424939. DOI: 10.1016/j.xkme.2024.100894.

References

Kearney S, Gangano A, Barrus D, Rehrauer K, Reid T, Navaratne P . Axially Chiral Cannabinoids: Design, Synthesis, and Cannabinoid Receptor Affinity. J Am Chem Soc. 2023; 145(25):13581-13591. PMC: 11392426. DOI: 10.1021/jacs.3c00129. View

Salau O, Bagde A, Kalvala A, Singh M . Enhancement of transdermal permeation of cannabinoids and their pharmacodynamic evaluation in rats. Int J Pharm. 2022; 624:122016. PMC: 9812589. DOI: 10.1016/j.ijpharm.2022.122016. View

Busquets-Garcia A, Bolanos J, Marsicano G . Metabolic Messengers: endocannabinoids. Nat Metab. 2022; 4(7):848-855. DOI: 10.1038/s42255-022-00600-1. View

Ramot Y, Olah A, Paus R . Cover Image: Neuroendocrine treatment of inherited keratin disorders by cannabinoids?. Br J Dermatol. 2018; 178(6):1469. DOI: 10.1111/bjd.16570. View

Di Meo C, Tortolani D, Standoli S, Angelucci C, Fanti F, Leuti A . Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes. Int J Mol Sci. 2022; 23(10). PMC: 9145865. DOI: 10.3390/ijms23105430. View

Wronski A, Jarocka-Karpowicz I, Stasiewicz A, Skrzydlewska E . Phytocannabinoids in the Pharmacotherapy of Psoriasis. Molecules. 2023; 28(3). PMC: 9920113. DOI: 10.3390/molecules28031192. View

Navarro G, Varani K, Lillo A, Vincenzi F, Rivas-Santisteban R, Raich I . Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB, CB and CB/CB heteromer receptors. Pharmacol Res. 2020; 159:104940. DOI: 10.1016/j.phrs.2020.104940. View

Olah A, Markovics A, Szabo-Papp J, Szabo P, Stott C, Zouboulis C . Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment. Exp Dermatol. 2016; 25(9):701-7. DOI: 10.1111/exd.13042. View

Norooznezhad A, Norooznezhad F . Cannabinoids: Possible agents for treatment of psoriasis via suppression of angiogenesis and inflammation. Med Hypotheses. 2017; 99:15-18. DOI: 10.1016/j.mehy.2016.12.003. View

10.

Cintosun A, Lara-Corrales I, Pope E . Mechanisms of Cannabinoids and Potential Applicability to Skin Diseases. Clin Drug Investig. 2020; 40(4):293-304. DOI: 10.1007/s40261-020-00894-7. View

11.

Silvestri C, Paris D, Martella A, Melck D, Guadagnino I, Cawthorne M . Two non-psychoactive cannabinoids reduce intracellular lipid levels and inhibit hepatosteatosis. J Hepatol. 2015; 62(6):1382-90. DOI: 10.1016/j.jhep.2015.01.001. View

12.

Todurga Seven Z, Tombulturk F, Gokdemir S, Ozyazgan S . The Effects of the Heat Shock Protein 90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin, Cannabinoid Agonist WIN 55,212-2, and Nitric Oxide Synthase Inhibitor Nω-Nitro-L-Arginine Methyl Ester Hydrochloride on the Serotonin and Dry Skin-Induced.... Int Arch Allergy Immunol. 2021; 183(4):443-452. DOI: 10.1159/000520509. View

13.

Carvalho A, Hansen E, Kayser O, Carlsen S, Stehle F . Designing microorganisms for heterologous biosynthesis of cannabinoids. FEMS Yeast Res. 2017; 17(4). PMC: 5812543. DOI: 10.1093/femsyr/fox037. View

14.

Lipina C, Hundal H . Modulation of cellular redox homeostasis by the endocannabinoid system. Open Biol. 2016; 6(4):150276. PMC: 4852457. DOI: 10.1098/rsob.150276. View

15.

Han K, Lim S, Ryu J, Lee C, Kim Y, Kang J . CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages. Cardiovasc Res. 2009; 84(3):378-86. DOI: 10.1093/cvr/cvp240. View

16.

Golliher A, Tenorio A, Dimauro N, Mairata N, Holguin F, Maio W . Using (+)-Carvone to access novel derivatives of (+)--Cannabidiol: the first asymmetric syntheses of (+)--CBDP and (+)--CBDV. Tetrahedron Lett. 2021; 67. PMC: 8513745. DOI: 10.1016/j.tetlet.2021.152891. View

17.

Stebulis J, Johnson D, Rossetti R, Burstein S, Zurier R . Ajulemic acid, a synthetic cannabinoid acid, induces an antiinflammatory profile of eicosanoids in human synovial cells. Life Sci. 2008; 83(19-20):666-70. DOI: 10.1016/j.lfs.2008.09.004. View

18.

Leong T, Fearon U, Veale D . Angiogenesis in psoriasis and psoriatic arthritis: clues to disease pathogenesis. Curr Rheumatol Rep. 2005; 7(4):325-9. DOI: 10.1007/s11926-005-0044-5. View

19.

Wilkinson J, Williamson E . Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. J Dermatol Sci. 2006; 45(2):87-92. DOI: 10.1016/j.jdermsci.2006.10.009. View

20.

Atalay S, Dobrzynska I, Gegotek A, Skrzydlewska E . Cannabidiol protects keratinocyte cell membranes following exposure to UVB and hydrogen peroxide. Redox Biol. 2020; 36:101613. PMC: 7327251. DOI: 10.1016/j.redox.2020.101613. View